US FDA approves first drug for neurological symptoms of type 3 Gaucher disease

Infilbray is approved for adults and children who weigh at least 15 kilograms, giving eligible patients a treatment for neurological symptoms that previously had no approved drug.
In this article
The US Food and Drug Administration approved Infilbray (venglustat) tablets on 18 November 2026, as the first treatment for neurological symptoms of type 3 Gaucher disease. The approval covers adults and children who weigh at least 15 kilograms, or about 33 pounds, and was granted to Genzyme Corporation, a Sanofi company.
Type 3 Gaucher disease is a rare inherited condition in which a deficient or faulty enzyme prevents the body from properly breaking down fatty substances. These build up in organs, tissues and the brain. The disease can cause progressively worsening problems with balance, coordination, speech, memory and thinking.
For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,
What the trial found
The FDA based its approval on a randomized, double-blind study at multiple centers involving 43 patients aged 12 and older. Neither patients nor researchers knew which treatment participants received. All had previously received enzyme replacement therapy and had reached a stable state in the disease’s effects outside the nervous system. The approval also covers eligible children younger than those studied.
Participants received either Infilbray orally once daily or enzyme replacement therapy by infusion every two weeks for 52 weeks. Enzyme replacement therapy in the comparison treated non-neurological effects of the disease. The FDA said the Infilbray group improved relative to the comparison group on a combined measure of thinking and ataxia, a loss of muscle control and coordination. The agency did not specify the size or precision of the improvement.
Risks and further results
The FDA said the most frequently reported side effects included gastrointestinal symptoms and effects on mood. Serious psychiatric risks, including suicidal thoughts and behavior, have also been reported. Animal studies identified potential risks of clouded vision in younger patients and harm to fetal development if the drug is taken during pregnancy.
Sanofi said on 28 May 2026, that the FDA had granted the application priority review and set a target decision date of 25 November 2026. The company said the study was continuing and that results from its open-label phase, in which participants know their treatment, would be presented when available.
Follow AveNews
Earlier in Science
SecurityMBDA Deutschland and ATMOS sign orbital strike agreement
The companies plan to study a conventional defense capability that would combine military payloads with orbital transport and atmospheric re-entry.
2 min
Physics, Maths & DiscoveriesMIT researchers build flying robot that lands on a sunflower
The tiny robot carries its own sensors and computer, but it still needs external power and received joystick commands for the landing.
2 min
Earth30 countries pursue fossil-fuel treaty outside UN process
The bloc announced its size at COP31 as governments sought a separate route to address coal, oil and gas. A treaty remains a proposal, with negotiations and ratification still ahead.
2 min
